Peter Hjelmstrom
Ideon Science Park
Lund, M 22370, Sweden
Lund, M 22370, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
VigiBase: Resource Profile Update with a Summary of Global Patterns and Trends in Adverse Event Reports for Medicines and Vaccines.
Journal: Drug safety
Published: September 12, 2025
Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use: A Post Hoc Analysis of a Randomized Clinical Trial.
Journal: JAMA network open
Published: June 25, 2024
Pharmacokinetic-pharmacodynamic analysis of drug liking blockade by buprenorphine subcutaneous depot (CAM2038) in participants with opioid use disorder.
Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
Published: November 09, 2022
Oxycodone-related deaths in Sweden 2006-2018.
Journal: Drug and alcohol dependence
Published: June 22, 2021
Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.
Journal: JAMA network open
Published: May 10, 2021
Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder.
Journal: Patient preference and adherence
Published: March 18, 2021
Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone.
Journal: Drug and alcohol dependence
Published: April 25, 2020
Methadone-related deaths among youth and young adults in Sweden 2006-15.
Journal: Addiction (Abingdon, England)
Published: January 14, 2020
Optimal dose of buprenorphine in opioid use disorder treatment: a review of pharmacodynamic and efficacy data.
Journal: Drug development and industrial pharmacy
Published: January 10, 2020
What place for prolonged-release buprenorphine depot-formulation Buvidal® in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine.
Journal: Expert opinion on drug delivery
Published: August 01, 2019
Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
Journal: Journal of addictive diseases
Published: June 09, 2016
Last Updated: 09/26/2026